ClinicalTrials.gg
CompletedNCT05075408NIKAIA 1Updated May 1, 2026Results posted

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

A Phase 2/3 interventional study of Nemolizumab and Nemolizumab in Chronic Kidney Disease Associated Moderate to Severe Pruritus, sponsored by Galderma R&D. Completed at 64 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 170 open to participants now, 218 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
179th of 819
258 · median 72
Started
2022
with 56 others
Phase 2/3
13 of 988
1 open now
Registered
719th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 179th largest by enrollment of the 819 interventional ones that give a count, is one of 57 that started in 2022, is one of 13 in phase 2/3, and was the 719th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

170 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy of nemolizumab compared to placebo at reducing the intensity of pruritus after a 12-week treatment period in adult hemodialysis participants with moderate to severe pruritus.

03

Conditions studied

  • Chronic Kidney Disease Associated Moderate to Severe Pruritus

Keywords

  • Chronic Kidney Disease
  • Moderate to Severe Pruritus
  • Nemolizumab
  • CD14152
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged >= 18 years at the screening visit.
  2. Had end-stage kidney disease (ESKD) and had been on hemodialysis three times per week for at least three months prior to the start of screening.

    Note 1: Participants who required an occasional additional hemodialysis treatment to manage fluid overload might be enrolled as long as it was anticipated that no more than one such treatment would be required in any given week.

    Note 2: Participants had received in-home hemodialysis might participated as long as they had switched to in-center hemodialysis at least two weeks prior to screening and plan to remain on in-center hemodialysis for the duration of the study.

  3. Hemodialysis participants meeting the Kidney Outcome Quality Initiative Guidelines of hemodialysis adequacy within 60 days of screening, two:

    •Single-poolsKt/V measurements of at least 1.2.

  4. Pruritus for >= three months (documented pruritus with no etiology identified other than CKD by medical record, previous physician's letter/statement, or a written conversation of site investigators based on the medical history obtained from the participant).
  5. WI NRS score >= 5.0 at the screening and baseline visit. Screening WI NRS score would be determined by a single WI NRS assessment (score ranging from 0 to 10) for the 24-hour period immediately preceding the screening visit. Baseline WI NRS score would be determined based on the weekly average of daily WI NRS scores (score ranging from 0 to 10) during the seven days immediately preceding baseline (rounding was not permitted). A minimum of four daily scores out of the seven days immediately preceding baseline was required for this calculation.
  6. Women of (WOCBP) (i.e., fertile, following menarche and until becoming unless permanently sterile) must agreed either to commit to true abstinence throughout the study and for 12 weeks after the last study drug injection, when this was in line with the preferred and usual lifestyle of the participant, or to use an adequate and approved method of throughout the study and for 12 weeks after the last study injection.

    Adequate and approved methods of contraception applicable for the participant and/or her partner were defined below:

    • Progestogen-only oral hormonal contraception.
    • Combination of male condom with cap, diaphragm, or sponge with spermicide (double-barrier methods).
    • Combined (estrogen- and progestogen-containing) oral, intravaginal, or transdermal hormonal contraception.
    • Injectable or implanted hormonal contraception.
    • Intrauterine devices or intrauterine hormone releasing system.
    • Bilateral tubal ligation or tube insert (such as the Essure system) at least three months before the study.
    • Bilateral vasectomy of partner at least three months before the study.
  7. Women were considered to be of non-childbearing potential if they meet one of the following criteria:

    • Absence of menstrual bleeding for one year prior to screening without any other medical reason, confirmed with follicle stimulating hormone (FSH) level in the postmenopausal range.
    • Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least three months before screening.

    Note: Bilateral tubal ligation was not accepted as reason for non-childbearing potential.

  8. Participant was willing and able to comply with all time commitments and procedural requirements of the clinical study protocol.
  9. Understands and signs an form (ICF) before any procedure(s) were performed.

Exclusion criteria

Exclusion Criteria:

  1. Body weight less than (\<) 30 kg.
  2. Pruritus caused by a concomitant condition unrelated to ESKD (e.g., dermatologic or systemic disorders such as, but not limited to atopic dermatitis (AD), psoriasis, prurigo nodularis (PN), Chronic T- cell Lymphoma, Leukemia or cholestatic liver disease).
  3. Localized itch of only the palms of the hands and/or soles of the feet.
  4. Pruritus present only during hemodialysis session.
  5. History of or anticipated non-compliance with hemodialysis (i.e, such that it would adversely affect the conduct of the study or significantly change dialysis adequacy during the study) in the opinion of the investigator.
  6. Class IV symptoms or myocardial infarction within three months prior to screening.
  7. History of stroke or within six months prior to screening.
  8. Participants meeting one or more of the following criteria at screening or baseline:

    • Had an exacerbation of asthma requiring hospitalization in the preceding 12 months.
    • Reporting asthma that had not been well-controlled (i.e. symptoms occurring on greater than (>) two days per week, night time awakenings two or more times per week, or some interference with normal activities) during the preceding three months.
    • Asthma Control Test (ACT) \<= 19 (only for participants with a history of asthma).
  9. Cutaneous infection within one week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within two weeks before the baseline visit.
  10. Any confirmed or suspected coronavirus disease (COVID-19) infection within two weeks before the screening or baseline visit. Participants might be rescreened after the infection had resolved. Resolution of COVID-19 infection could be confirmed by recovery assessment methods, as described in the protocol.
  11. Positive serology results ( surface antigen [HbsAg] or hepatitis B core antibody [HbcAb], [HCV] antibody with positive confirmatory test for hepatitis C virus [HCV] (e.g., HCV polymerase chain reaction [PRC]), or [HIV] antibody) at the screening visit.

    Note: Participants with a positive HbcAb and a negative HbsAg could be included in this clinical study if hepatitis B surface antibody was positive (considered immune after a natural infection or vaccination). Participants who were positive for HCV antibody and negative for HCV RNA might be enrolled.

    In the event of rescreening, the serology tests results (e.g., HBV, HCV, HIV) from the previous screening could be used by the investigator to assess the eligibility of rescreened participants if those tests were performed within six weeks prior to the baseline visit.

  12. Known active or untreated latent tuberculosis (TB) infection or history of either untreated or inadequately treated active or latent TB according to the local applicable guidelines.

    Note: Participants who had a documented history of completion of an appropriate TB treatment regimen for latent or active TB with no history of re-exposure to TB since their treatment was completed were eligible to participate in the study.

  13. Known or suspected beyond that expected due to end-stage kidney disease and its comorbidities or unusually frequent, recurrent, severe, or prolonged infections as per investigator judgment.
  14. History of lymphoproliferative disease or history of of any organ system within the last five years, except for (1) basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that had been treated and had no evidence of recurrence in the last 12 weeks before the baseline visit, or (2) actinic keratoses that had been treated.
  15. Pregnant women (positive serum pregnancy test result at any visits), breastfeeding women, or women planning a pregnancy during the clinical study.
  16. In the opinion of the investigator the participant had any medical or psychological condition that could pose undue risk to the participant, prevent study completion, or adversely affect the validity or interpretability of the study measurements or interfered with study assessments.
  17. Any laboratory abnormalities, such as but not limited to elevated (ALT) or aspartate aminotransferase (AST) (>3 * [ULN]) in combination with elevated (>2 * ULN), during the screening period that might put the participant at significant risk according to the investigator's judgment, if he/she participated in the clinical study.
  18. Planned or expected major surgical procedure during the clinical study, including a scheduled kidney transplant during the study.
  19. Had not adhered to the restrictions in the selected medications prior to screening or was not expected to be compliant with restrictions during the study.
  20. Requiring rescue therapy for pruritus during the screening period or expected to require rescue therapy within 4 weeks following the Baseline visit.
  21. Previous treatment with nemolizumab.
  22. History of (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g. monoclonal antibody) or to any of the study drug .
  23. Currently participating or participated in any other study of an drug or device, within the past four weeks (or five half-lives of the investigational medication, whichever was longer) before the screening visit.
  24. History of alcohol or substance abuse within six months of the screening visit.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Nemolizumab 30 mg

    Drug: Nemolizumab

  • Experimental
    Nemolizumab 60 mg

    Drug: Nemolizumab

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Participants received a loading dose of 60 mg nemolizumab at Baseline followed by 2 Subcutaneous (SC) injections for a total dose of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.

    Also known as: CD14152

  • Participants received 2 SC injections of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.

    Also known as: CD14152

  • DrugPlacebo

    Participants received 2 SC injections of 30 mg placebo-matched to nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.

06

What researchers measure

Primary outcomes

  1. Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12

    Responders are defined as participants with an improvement of \>= 4 in WI NRS from baseline at Week 12 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or Adverse event(AE)/death related to study drug. The WI NRS is a scale that is used by responders to report intensity of their worst pruritus (itch) during last 24 hours. Participants were asked following question: For worst itch intensity:"On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated worse outcome. Percentage of responders with an improvement of WI NRS \>= 4 from Baseline at Week 12 is reported here. Missing data due to discontinuation from the study prior to Week 12 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 12

    Responders are defined as participants with an improvement of \>= 3 in WI NRS from baseline at Week 12 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. The WI NRS is a scale that is used by the responders to report the intensity of their worst pruritus (itch) during the last 24 hours. Participants were asked the following question: For worst itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated worse outcome. Percentage of responders with an improvement of WI NRS \>= 3 from Baseline at Week 12 is reported here. Missing data due to discontinuation from the study prior to Week 12 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

    Time frame: Baseline, Week 12

  2. Percentage of Responders With an Improvement of WI NRS >= 4 From Baseline at Week 4

    Responders are defined as participants with an improvement of \>= 4 in WI NRS from baseline at Week 4 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. The WI NRS is a scale that is used by the responders to report the intensity of their worst pruritus (itch) during the last 24 hours. Participants were asked the following question: For worst itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated worse outcome. Percentage of responders with an improvement of WI NRS \>= 4 from Baseline at Week 4 is reported here. Missing data due to discontinuation from the study prior to Week 4 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

    Time frame: Baseline, Week 4

  3. Percentage of Responders With an Improvement of Sleep Disturbance Numerical Rating Scale (SD NRS) >= 4 From Baseline at Week 12

    Responders are participants with an improvement \>= 4 in SD NRS from baseline at Week 12 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. SD NRS is a scale used by participants to report degree of their sleep loss related to chronic kidney disease with associated pruritus (CKD-aP ). Participants were asked following question: "On a scale of 0 to 10, with 0 being 'no sleep loss related to the symptoms of pruritus' and 10 being 'I did not sleep at all due to the symptoms of pruritus', how would you rate your sleep last night?". Higher scores indicated worse outcome. Percentage of responders with an improvement of SD NRS \>= 4 from Baseline at Week 12 is reported here. Missing data due to discontinuation from study prior to Week 12 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

    Time frame: Baseline, Week 12

  4. Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 4

    Responders are defined as participants with an improvement of \>= 3 in WI NRS from baseline at Week 4 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. The WI NRS is a scale that is used by the responders to report the intensity of their worst pruritus (itch) during the last 24 hours. Participants were asked the following question: For worst itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated worse outcome. Percentage of responders with an improvement of WI NRS \>= 3 from Baseline at Week 4 is reported here. Missing data due to discontinuation from the study prior to Week 4 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

    Time frame: Baseline, Week 4

  5. Percentage of Responders With an Improvement of SD NRS >= 4 From Baseline at Week 4

    Responders are defined as participants with an improvement \>= 4 in SD NRS from baseline at Week 4 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. The SD NRS is a scale used by participants to report the degree of their sleep loss related to CKD-aP. Participants were asked the following question: "On a scale of 0 to 10, with 0 being 'no sleep loss related to the symptoms of pruritus' and 10 being 'I did not sleep at all due to the symptoms of pruritus', how would you rate your sleep last night?". Higher scores indicated worse outcome. Percentage of responders with an improvement of SD NRS \>= 4 from Baseline at Week 4 is reported here. Missing data due to discontinuation from the study prior to Week 4 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

    Time frame: Baseline, Week 4

07

Results

Posted Feb 20, 2025

Participant flow

This study was conducted at 53 study sites in 4 countries from 18 March 2022 to 04 January 2024.

Participant flow — Overall Study
MilestoneNemolizumab 30 mgNemolizumab 60 mgPlacebo
Started888585
Completed727172
Not completed161413
Withdrew: Withdrawal by subject534
Withdrew: Adverse event578
Withdrew: Protocol violation010
Withdrew: Lost to follow-up211
Withdrew: Physician decision100
Withdrew: Other-unspecified320

Outcome measures

PrimaryPercentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12

Responders are defined as participants with an improvement of \>= 4 in WI NRS from baseline at Week 12 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or Adverse event(AE)/death related to study drug. The WI NRS is a scale that is used by responders to report intensity of their worst pruritus (itch) during last 24 hours. Participants were asked following question: For worst itch intensity:"On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated worse outcome. Percentage of responders with an improvement of WI NRS \>= 4 from Baseline at Week 12 is reported here. Missing data due to discontinuation from the study prior to Week 12 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

Time frame:
Baseline, Week 12
Reported as:
Number · Percentage of Participants
Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12
Percentage of ParticipantsNemolizumab 30 mgNemolizumab 60 mgPlacebo
Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 1238.547.732.4
Statistical analysis
  • Nemolizumab 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3696 (Threshold of significance at 0.025.) · Strata adjusted percentage difference: 7.0 · 97.5% CI -10.6 to 24.6
  • Nemolizumab 60 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0686 (Threshold of significance at 0.025.) · Strata adjusted percentage difference: 14.5 · 97.5% CI -3.1 to 32.2
SecondaryPercentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 12

Responders are defined as participants with an improvement of \>= 3 in WI NRS from baseline at Week 12 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. The WI NRS is a scale that is used by the responders to report the intensity of their worst pruritus (itch) during the last 24 hours. Participants were asked the following question: For worst itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated worse outcome. Percentage of responders with an improvement of WI NRS \>= 3 from Baseline at Week 12 is reported here. Missing data due to discontinuation from the study prior to Week 12 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

Time frame:
Baseline, Week 12
Reported as:
Number · Percentage of Participants
Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 12
Percentage of ParticipantsNemolizumab 30 mgNemolizumab 60 mgPlacebo
Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 1249.360.647.1
Statistical analysis
  • Nemolizumab 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.5909 · Strata adjusted percentage difference: 4.3 · 97.5% CI -13.8 to 22.3
  • Nemolizumab 60 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1112 · Strata adjusted percentage difference: 12.9 · 97.5% CI -5.5 to 31.4
SecondaryPercentage of Responders With an Improvement of WI NRS >= 4 From Baseline at Week 4

Responders are defined as participants with an improvement of \>= 4 in WI NRS from baseline at Week 4 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. The WI NRS is a scale that is used by the responders to report the intensity of their worst pruritus (itch) during the last 24 hours. Participants were asked the following question: For worst itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated worse outcome. Percentage of responders with an improvement of WI NRS \>= 4 from Baseline at Week 4 is reported here. Missing data due to discontinuation from the study prior to Week 4 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

Time frame:
Baseline, Week 4
Reported as:
Number · Percentage of Participants
Percentage of Responders With an Improvement of WI NRS >= 4 From Baseline at Week 4
Percentage of ParticipantsNemolizumab 30 mgNemolizumab 60 mgPlacebo
Percentage of Responders With an Improvement of WI NRS >= 4 From Baseline at Week 424.326.67.4
Statistical analysis
  • Nemolizumab 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0034 · Strata adjusted percentage difference: 17.3 · 97.5% CI 4.3 to 30.4
  • Nemolizumab 60 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0025 · Strata adjusted percentage difference: 17.1 · 97.5% CI 4.5 to 29.8
SecondaryPercentage of Responders With an Improvement of Sleep Disturbance Numerical Rating Scale (SD NRS) >= 4 From Baseline at Week 12

Responders are participants with an improvement \>= 4 in SD NRS from baseline at Week 12 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. SD NRS is a scale used by participants to report degree of their sleep loss related to chronic kidney disease with associated pruritus (CKD-aP ). Participants were asked following question: "On a scale of 0 to 10, with 0 being 'no sleep loss related to the symptoms of pruritus' and 10 being 'I did not sleep at all due to the symptoms of pruritus', how would you rate your sleep last night?". Higher scores indicated worse outcome. Percentage of responders with an improvement of SD NRS \>= 4 from Baseline at Week 12 is reported here. Missing data due to discontinuation from study prior to Week 12 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

Time frame:
Baseline, Week 12
Reported as:
Number · Percentage of Participants
Percentage of Responders With an Improvement of Sleep Disturbance Numerical Rating Scale (SD NRS) >= 4 From Baseline at Week 12
Percentage of ParticipantsNemolizumab 30 mgNemolizumab 60 mgPlacebo
Percentage of Responders With an Improvement of Sleep Disturbance Numerical Rating Scale (SD NRS) >= 4 From Baseline at Week 1227.742.625.3
Statistical analysis
  • Nemolizumab 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.5788 · Strata adjusted percentage difference: 3.7 · 97.5% CI -12.5 to 19.8
  • Nemolizumab 60 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0303 · Strata adjusted percentage difference: 16.5 · 97.5% CI -0.8 to 33.9
SecondaryPercentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 4

Responders are defined as participants with an improvement of \>= 3 in WI NRS from baseline at Week 4 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. The WI NRS is a scale that is used by the responders to report the intensity of their worst pruritus (itch) during the last 24 hours. Participants were asked the following question: For worst itch intensity: "On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable', how would you rate your itch at the worst moment during the previous 24 hours?". Higher scores indicated worse outcome. Percentage of responders with an improvement of WI NRS \>= 3 from Baseline at Week 4 is reported here. Missing data due to discontinuation from the study prior to Week 4 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

Time frame:
Baseline, Week 4
Reported as:
Number · Percentage of Participants
Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 4
Percentage of ParticipantsNemolizumab 30 mgNemolizumab 60 mgPlacebo
Percentage of Responders With an Improvement of WI NRS >= 3 From Baseline at Week 436.535.012.8
Statistical analysis
  • Nemolizumab 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0006 · Strata adjusted percentage difference: 24.2 · 97.5% CI 8.8 to 39.6
  • Nemolizumab 60 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0021 · Strata adjusted percentage difference: 20.8 · 97.5% CI 6.0 to 35.7
SecondaryPercentage of Responders With an Improvement of SD NRS >= 4 From Baseline at Week 4

Responders are defined as participants with an improvement \>= 4 in SD NRS from baseline at Week 4 without use of rescue therapies and without treatment discontinuation due to lack of efficacy or AE/death related to study drug. The SD NRS is a scale used by participants to report the degree of their sleep loss related to CKD-aP. Participants were asked the following question: "On a scale of 0 to 10, with 0 being 'no sleep loss related to the symptoms of pruritus' and 10 being 'I did not sleep at all due to the symptoms of pruritus', how would you rate your sleep last night?". Higher scores indicated worse outcome. Percentage of responders with an improvement of SD NRS \>= 4 from Baseline at Week 4 is reported here. Missing data due to discontinuation from the study prior to Week 4 or any other reason (e.g., insufficient eDiary completion) were imputed using multiple imputation under missing at random assumption (results were combined using Rubin's formulae).

Time frame:
Baseline, Week 4
Reported as:
Number · Percentage of Participants
Percentage of Responders With an Improvement of SD NRS >= 4 From Baseline at Week 4
Percentage of ParticipantsNemolizumab 30 mgNemolizumab 60 mgPlacebo
Percentage of Responders With an Improvement of SD NRS >= 4 From Baseline at Week 416.123.62.8
Statistical analysis
  • Nemolizumab 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0028 · Strata adjusted percentage difference: 14.0 · 97.5% CI 3.8 to 24.1
  • Nemolizumab 60 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0003 · Strata adjusted percentage difference: 19.0 · 97.5% CI 7.6 to 30.5

Adverse events

Collected over From baseline up to Week 20. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nemolizumab 30 mg4/86 (4.7%)33/86 (38.4%)29/86 (33.7%)
Nemolizumab 60 mg4/84 (4.8%)22/84 (26.2%)25/84 (29.8%)
Placebo5/85 (5.9%)27/85 (31.8%)19/85 (22.4%)
Most frequent serious events
Showing 10 of 107
Most frequent serious events
EventNemolizumab 30 mgNemolizumab 60 mgPlacebo
PneumoniaInfections and infestations2/861/845/85
Acute myocardial infarctionCardiac disorders4/861/841/85
HypervolaemiaMetabolism and nutrition disorders4/861/843/85
Cardiac arrestCardiac disorders1/862/843/85
HyperkalaemiaMetabolism and nutrition disorders3/860/841/85
SepsisInfections and infestations1/860/842/85
Cardiac failure acuteCardiac disorders0/860/842/85
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/861/842/85
DyspnoeaRespiratory, thoracic and mediastinal disorders0/861/842/85
Pleural effusionRespiratory, thoracic and mediastinal disorders0/860/842/85
Most frequent other events
Showing 10 of 32
Most frequent other events
EventNemolizumab 30 mgNemolizumab 60 mgPlacebo
HyperkalaemiaMetabolism and nutrition disorders3/864/843/85
DiarrhoeaGastrointestinal disorders1/861/844/85
VomitingGastrointestinal disorders3/863/843/85
CoughRespiratory, thoracic and mediastinal disorders0/863/842/85
Dialysis hypotensionVascular disorders0/863/841/85
FallInjury, poisoning and procedural complications3/860/843/85
Arteriovenous fistula site complicationInjury, poisoning and procedural complications3/860/840/85
DyspnoeaRespiratory, thoracic and mediastinal disorders3/861/842/85
Atrial fibrillationCardiac disorders3/861/840/85
DizzinessNervous system disorders3/860/841/85

Baseline characteristics

The intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Nemolizumab 30 mgNemolizumab 60 mgPlaceboTotal
Mean58.3 ± 12.9959.0 ± 13.0058.4 ± 11.9858.6 ± 12.63
Sex: Female, Male
Sex: Female, Male(Participants)Nemolizumab 30 mgNemolizumab 60 mgPlaceboTotal
Female413929109
Male474656149
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nemolizumab 30 mgNemolizumab 60 mgPlaceboTotal
Hispanic or Latino423140113
Not Hispanic or Latino465445145
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nemolizumab 30 mgNemolizumab 60 mgPlaceboTotal
American Indian or Alaska Native0213
Asian3227
Native Hawaiian or Other Pacific Islander0000
Black or African American21322477
White564350149
More than one race0000
Unknown or Not Reported86822
08

Study locations

64 sites
  • Galderma Investigational Site 9989
    Bakersfield, California 93309, United States
  • Galderma Investigational Site 9991
    Glendale, California 91205, United States
  • Galderma Investigational Site 7018
    Glendale, California 91206, United States
  • Galderma Investigational Site 7015
    La Palma, California 90623, United States
  • Galderma Investigational Site 9996
    Los Angeles, California 90048, United States
  • Galderma Investigational Site 9978
    Lynwood, California 90262, United States
  • Galderma Investigational Site 7017
    Riverside, California 92505, United States
  • Galderma Investigational Site 9973
    Tarzana, California 91356, United States
  • Galderma Investigational Site 7028
    Victorville, California 92392, United States
  • Galderma Investigational Site 9964
    Victorville, California 92394-1868, United States
  • Galderma Investigational Site 7003
    Whittier, California 90603, United States
  • Galderma Investigational Site 9971
    Denver, Colorado 80230, United States
  • Galderma Investigational Site 9988
    Bloomfield, Connecticut 06002, United States
  • Galderma Investigational Site 9980
    Middlebury, Connecticut 06762, United States
  • Galderma Investigational Site 9970
    Boca Raton, Florida 33421, United States
  • Galderma Investigational Site 7037
    Coral Gables, Florida 33134, United States
  • Galderma Investigational Site 7026
    Hollywood, Florida 33021, United States
  • Galderma Investigational Site 9965
    Miami, Florida 33125, United States
  • Galderma Investigational Site7016
    Miami, Florida 33155, United States
  • Galderma Investigational Site 7032
    Sanford, Florida 32771, United States
  • Galderma Investigational Site 7004
    Tampa, Florida 33603, United States
  • Galderma Investigational Site 7025
    Tampa, Florida 33603, United States
  • Galderma Investigational Site 7027
    Columbus, Georgia 31904, United States
  • Galderma Investigational Site 9983
    Overland Park, Kansas 66210, United States
  • Galderma Investigational Site 9972
    Wichita, Kansas 67214, United States
  • Galderma Investigational Site 9963
    Roseville, Michigan 48066, United States
  • Galderma Investigational Site 7020
    Edina, Minnesota 55435, United States
  • Galderma Investigational Site 9982
    Minneapolis, Minnesota 55404, United States
  • Galderma Investigational Site 7035
    Kansas City, Missouri 64111, United States
  • Galderma Investigational Site 9962
    Las Vegas, Nevada 89128, United States
  • Galderma Investigational Site 7038
    Fresh Meadows, New York 11365, United States
  • Galderma Investigational Site 9998
    Great Neck, New York 11021, United States
  • Galderma Investigational Site 9995
    The Bronx, New York 10461, United States
  • Galderma Investigational Site 7007
    Winston-Salem, North Carolina 27103, United States
  • Galderma Investigational Site 9992
    Roseburg, Oregon 97471, United States
  • Galderma Investigational Site 9999
    Spartanburg, South Carolina 29306, United States
  • Galderma Investigational Site 9967
    Chattanooga, Tennessee 37404, United States
  • Galderma Investigational Site 7039
    Arlington, Texas 76015, United States
  • Galderma Investigational Site 7040
    Dallas, Texas 75231, United States
  • Galderma Investigational Site 9966
    El Paso, Texas 79925, United States
  • Galderma Investigational Site 9977
    Greenville, Texas 75402, United States
  • Galderma Investigational Site 7011
    Houston, Texas 77054, United States
  • Galderma Investigational Site 7022
    McKinney, Texas 75069, United States
  • Galderma Investigational Site 7010
    San Antonio, Texas 78258, United States
  • Galderma Investigational Site 7019
    The Woodlands, Texas 77384, United States
  • Galderma Investigational Site 9968
    Norfolk, Virginia 23502, United States
  • Galderma Investigational Site 9969
    Wauwatosa, Wisconsin 53226, United States
  • Galderma Investigational Site 6301
    Budapest, 1076, Hungary
  • Galderma Investigational Site 6304
    Kecskemét, 6000, Hungary
  • Galderma Investigational Site 6305
    Miskolc, 3526, Hungary
  • Galderma Investigational Site 6310
    Szentes, 6600, Hungary
  • Galderma Investigational Site 6298
    Szombathely, 9700, Hungary
  • Galderma Investigational Site 6294
    Brodnica, 87-300, Poland
  • Galderma Investigational Site 6296
    Lodz, 90-153, Poland
  • Galderma Investigational Site 6293
    Olkusz, 32-300, Poland
  • Galderma Investigational Site 6297
    Wroclaw, 50-556, Poland
  • Galderma Investigational Site 6309
    Alcobendas, 28108, Spain
  • Galderma Investigational Site 6292
    Córdoba, 14004, Spain
  • Galderma Investigational Site 5580
    L'Hospitalet de Llobregat, 08097, Spain
  • Galderma Investigational Site 5171
    Madrid, 28040, Spain
  • Galderma Investigational Site 6190
    Madrid, 28046, Spain
  • Galderma Investigational Site 6278
    Manises, 46940, Spain
  • Galderma Investigational Site 6295
    Seville, 41009, Spain
  • Galderma Investigational Site 6311
    Valencia, 46017, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jan 2024, 21 months.

Results were first posted in Feb 2025, 1 year 1 month after primary completion. A results delay was requested in Dec 2024.

Of 11 phase 2/3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 56. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2021
First posted
Oct 12, 2021
StartActual
Mar 18, 2022
Primary completionActual
Jan 4, 2024
CompletionActual
Jan 4, 2024
Results delay requested
Dec 13, 2024
Results first posted
Feb 20, 2025
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05075408
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Oct 12, 2021
Start date
Mar 18, 2022
Primary completion
Jan 4, 2024
Completion
Jan 4, 2024
Results posted
Feb 20, 2025
Last update
May 1, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion